| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Salivary Gland Neoplasms | 109 | 2023 | 497 | 15.390 |
Why?
|
| Carcinoma, Adenoid Cystic | 59 | 2024 | 444 | 9.820 |
Why?
|
| Head and Neck Neoplasms | 148 | 2024 | 4148 | 6.030 |
Why?
|
| Carcinoma, Squamous Cell | 188 | 2024 | 5594 | 5.690 |
Why?
|
| Parotid Neoplasms | 31 | 2024 | 150 | 5.490 |
Why?
|
| Mouth Neoplasms | 67 | 2023 | 734 | 4.450 |
Why?
|
| DNA, Neoplasm | 127 | 2014 | 1958 | 4.260 |
Why?
|
| Carcinoma, Mucoepidermoid | 29 | 2023 | 141 | 4.260 |
Why?
|
| Carcinoma | 73 | 2023 | 2610 | 3.710 |
Why?
|
| Thyroid Neoplasms | 52 | 2019 | 1894 | 2.960 |
Why?
|
| Laryngeal Neoplasms | 31 | 2018 | 530 | 2.600 |
Why?
|
| Biomarkers, Tumor | 76 | 2024 | 10714 | 2.460 |
Why?
|
| Flow Cytometry | 127 | 2010 | 3042 | 2.450 |
Why?
|
| Translocation, Genetic | 15 | 2016 | 1286 | 2.240 |
Why?
|
| Oncogene Proteins, Fusion | 13 | 2019 | 797 | 2.200 |
Why?
|
| Carcinoma, Ductal | 7 | 2021 | 144 | 2.200 |
Why?
|
| Adenoma, Pleomorphic | 17 | 2012 | 63 | 2.050 |
Why?
|
| Tongue Neoplasms | 27 | 2018 | 253 | 2.040 |
Why?
|
| Ploidies | 65 | 2010 | 250 | 2.030 |
Why?
|
| Paranasal Sinus Neoplasms | 16 | 2020 | 285 | 1.920 |
Why?
|
| Immunohistochemistry | 105 | 2024 | 7645 | 1.830 |
Why?
|
| Leukoplakia, Oral | 13 | 2018 | 71 | 1.830 |
Why?
|
| Humans | 719 | 2024 | 271081 | 1.770 |
Why?
|
| World Health Organization | 7 | 2018 | 327 | 1.770 |
Why?
|
| Middle Aged | 389 | 2024 | 90521 | 1.750 |
Why?
|
| Salivary Ducts | 5 | 2021 | 55 | 1.720 |
Why?
|
| Male | 440 | 2024 | 128479 | 1.660 |
Why?
|
| Carcinoma, Acinar Cell | 8 | 2023 | 87 | 1.650 |
Why?
|
| Carcinoma, Papillary | 20 | 2018 | 566 | 1.570 |
Why?
|
| Trans-Activators | 24 | 2019 | 1626 | 1.550 |
Why?
|
| Adenocarcinoma | 47 | 2024 | 7919 | 1.550 |
Why?
|
| Microsatellite Repeats | 23 | 2017 | 627 | 1.490 |
Why?
|
| Aged | 315 | 2024 | 73545 | 1.490 |
Why?
|
| Female | 446 | 2024 | 149115 | 1.470 |
Why?
|
| Tumor Suppressor Protein p53 | 41 | 2024 | 3657 | 1.440 |
Why?
|
| Adult | 304 | 2024 | 82171 | 1.420 |
Why?
|
| Chromosomes, Human, Pair 3 | 15 | 2016 | 324 | 1.400 |
Why?
|
| Precancerous Conditions | 33 | 2018 | 1061 | 1.380 |
Why?
|
| Oropharyngeal Neoplasms | 17 | 2021 | 1162 | 1.290 |
Why?
|
| Genes, p53 | 31 | 2023 | 1140 | 1.280 |
Why?
|
| Nuclear Proteins | 30 | 2015 | 3435 | 1.280 |
Why?
|
| Salivary Glands | 17 | 2023 | 139 | 1.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 54 | 2024 | 9044 | 1.250 |
Why?
|
| Loss of Heterozygosity | 21 | 2016 | 623 | 1.240 |
Why?
|
| Aged, 80 and over | 155 | 2021 | 31078 | 1.210 |
Why?
|
| Cell Transformation, Neoplastic | 24 | 2024 | 2453 | 1.190 |
Why?
|
| Mutation | 58 | 2024 | 15904 | 1.190 |
Why?
|
| Adenoma | 21 | 2018 | 740 | 1.140 |
Why?
|
| ErbB Receptors | 28 | 2023 | 2375 | 1.110 |
Why?
|
| Tumor Suppressor Proteins | 27 | 2016 | 1900 | 1.100 |
Why?
|
| Nose Neoplasms | 11 | 2013 | 243 | 1.100 |
Why?
|
| NFI Transcription Factors | 5 | 2015 | 78 | 1.100 |
Why?
|
| DNA-Binding Proteins | 23 | 2019 | 4994 | 1.060 |
Why?
|
| Mouth Mucosa | 18 | 2018 | 224 | 1.040 |
Why?
|
| Transcription Factors | 26 | 2016 | 5416 | 1.010 |
Why?
|
| Papillomavirus Infections | 12 | 2024 | 999 | 0.990 |
Why?
|
| Neoplasm Proteins | 27 | 2015 | 3345 | 0.950 |
Why?
|
| Neoplasms, Multiple Primary | 11 | 2019 | 557 | 0.930 |
Why?
|
| Carcinoma, Neuroendocrine | 8 | 2020 | 742 | 0.910 |
Why?
|
| Papillomaviridae | 12 | 2021 | 636 | 0.890 |
Why?
|
| Adenolymphoma | 4 | 2008 | 25 | 0.890 |
Why?
|
| Chromosomes, Human, Pair 8 | 8 | 2015 | 329 | 0.880 |
Why?
|
| Receptors, Androgen | 4 | 2019 | 854 | 0.870 |
Why?
|
| Chromosome Aberrations | 16 | 2017 | 2035 | 0.850 |
Why?
|
| Genetic Heterogeneity | 6 | 2018 | 338 | 0.840 |
Why?
|
| Chromosomes, Human, Pair 1 | 4 | 2016 | 354 | 0.840 |
Why?
|
| Prognosis | 118 | 2024 | 22529 | 0.830 |
Why?
|
| Aneuploidy | 28 | 2008 | 383 | 0.820 |
Why?
|
| Chromosomes, Human, Pair 9 | 13 | 2015 | 298 | 0.810 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 13 | 2016 | 506 | 0.810 |
Why?
|
| Skin Neoplasms | 31 | 2021 | 4900 | 0.810 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 511 | 0.800 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 28 | 2017 | 3587 | 0.800 |
Why?
|
| Submandibular Gland Neoplasms | 5 | 2018 | 37 | 0.790 |
Why?
|
| DNA Methylation | 12 | 2015 | 2770 | 0.790 |
Why?
|
| RNA, Neoplasm | 22 | 2011 | 805 | 0.790 |
Why?
|
| Skull Base Neoplasms | 2 | 2020 | 339 | 0.780 |
Why?
|
| Neoplasm Recurrence, Local | 53 | 2023 | 10400 | 0.770 |
Why?
|
| Diagnosis, Differential | 40 | 2020 | 4838 | 0.770 |
Why?
|
| Promoter Regions, Genetic | 17 | 2015 | 3204 | 0.770 |
Why?
|
| Polymerase Chain Reaction | 35 | 2011 | 3472 | 0.760 |
Why?
|
| Genes, Tumor Suppressor | 19 | 2023 | 1127 | 0.760 |
Why?
|
| In Situ Hybridization, Fluorescence | 26 | 2019 | 2313 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-myb | 2 | 2011 | 50 | 0.740 |
Why?
|
| Receptor, Notch1 | 5 | 2022 | 216 | 0.720 |
Why?
|
| Neoplasm Invasiveness | 41 | 2020 | 4052 | 0.720 |
Why?
|
| Mandibular Neoplasms | 3 | 2010 | 77 | 0.720 |
Why?
|
| Neoplasm Metastasis | 36 | 2018 | 5317 | 0.720 |
Why?
|
| Neck Dissection | 18 | 2021 | 294 | 0.710 |
Why?
|
| Kidney Neoplasms | 27 | 2002 | 3109 | 0.710 |
Why?
|
| Adenocarcinoma, Follicular | 6 | 2018 | 131 | 0.700 |
Why?
|
| Chromosomes, Human, Pair 6 | 4 | 2011 | 203 | 0.700 |
Why?
|
| Melanoma | 14 | 2024 | 5597 | 0.700 |
Why?
|
| Biopsy, Needle | 32 | 2014 | 1382 | 0.690 |
Why?
|
| Proto-Oncogene Proteins | 18 | 2015 | 2617 | 0.680 |
Why?
|
| Adolescent | 98 | 2021 | 32783 | 0.680 |
Why?
|
| Polymorphism, Single Nucleotide | 18 | 2017 | 4642 | 0.670 |
Why?
|
| Neoplasm Staging | 80 | 2021 | 14020 | 0.670 |
Why?
|
| Gene Fusion | 5 | 2013 | 214 | 0.670 |
Why?
|
| Base Sequence | 27 | 2014 | 5417 | 0.670 |
Why?
|
| Mifepristone | 1 | 2019 | 180 | 0.660 |
Why?
|
| Cell Line, Tumor | 47 | 2024 | 14873 | 0.650 |
Why?
|
| Gene Expression Profiling | 15 | 2016 | 5143 | 0.650 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 367 | 0.650 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2019 | 168 | 0.650 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2019 | 82 | 0.640 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 104 | 0.640 |
Why?
|
| Cushing Syndrome | 1 | 2019 | 73 | 0.640 |
Why?
|
| Karyotyping | 13 | 2017 | 1064 | 0.630 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2019 | 207 | 0.620 |
Why?
|
| Human papillomavirus 16 | 4 | 2013 | 255 | 0.620 |
Why?
|
| Breast Neoplasms | 35 | 2023 | 16238 | 0.610 |
Why?
|
| Carcinoma, Verrucous | 3 | 2014 | 13 | 0.610 |
Why?
|
| Microbiota | 1 | 2024 | 548 | 0.600 |
Why?
|
| DNA | 17 | 2014 | 3045 | 0.600 |
Why?
|
| Proto-Oncogene Proteins c-kit | 6 | 2011 | 485 | 0.590 |
Why?
|
| Up-Regulation | 13 | 2020 | 2414 | 0.580 |
Why?
|
| Estrogen Receptor beta | 4 | 2007 | 149 | 0.580 |
Why?
|
| Carcinoid Tumor | 10 | 1997 | 282 | 0.580 |
Why?
|
| raf Kinases | 4 | 2012 | 80 | 0.570 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2017 | 402 | 0.570 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2018 | 1704 | 0.570 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2018 | 426 | 0.570 |
Why?
|
| Neoplasms, Muscle Tissue | 2 | 2009 | 23 | 0.560 |
Why?
|
| Calcium-Binding Proteins | 4 | 2013 | 542 | 0.560 |
Why?
|
| Disease Progression | 36 | 2020 | 6868 | 0.550 |
Why?
|
| Cyclins | 7 | 2003 | 465 | 0.540 |
Why?
|
| Phosphoproteins | 8 | 2011 | 1130 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-akt | 12 | 2018 | 2050 | 0.540 |
Why?
|
| Rhabdomyosarcoma | 5 | 2009 | 342 | 0.530 |
Why?
|
| Lacrimal Apparatus Diseases | 4 | 2020 | 144 | 0.530 |
Why?
|
| Lymphatic Metastasis | 36 | 2021 | 4969 | 0.520 |
Why?
|
| Signal Transduction | 26 | 2019 | 12044 | 0.520 |
Why?
|
| Gene Expression | 16 | 2016 | 3606 | 0.510 |
Why?
|
| RNA, Messenger | 29 | 2014 | 6343 | 0.510 |
Why?
|
| Saliva | 3 | 2008 | 238 | 0.510 |
Why?
|
| Clonal Evolution | 1 | 2017 | 250 | 0.510 |
Why?
|
| Receptor, ErbB-2 | 15 | 2023 | 2658 | 0.510 |
Why?
|
| Survival Analysis | 41 | 2018 | 9290 | 0.510 |
Why?
|
| Antineoplastic Agents | 30 | 2018 | 14636 | 0.510 |
Why?
|
| Ki-67 Antigen | 12 | 2015 | 675 | 0.500 |
Why?
|
| Paranasal Sinuses | 4 | 2020 | 64 | 0.500 |
Why?
|
| Iodine Radioisotopes | 1 | 2017 | 388 | 0.500 |
Why?
|
| Membrane Glycoproteins | 5 | 2009 | 1097 | 0.500 |
Why?
|
| Tumor Cells, Cultured | 42 | 2018 | 5759 | 0.490 |
Why?
|
| Immunoenzyme Techniques | 26 | 2013 | 1190 | 0.490 |
Why?
|
| Myoepithelioma | 5 | 2015 | 30 | 0.490 |
Why?
|
| Thyroid Gland | 7 | 2019 | 366 | 0.480 |
Why?
|
| Eye Neoplasms | 4 | 2020 | 257 | 0.480 |
Why?
|
| Chromosome Deletion | 8 | 1999 | 1048 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 26 | 2023 | 16720 | 0.470 |
Why?
|
| Endodermal Sinus Tumor | 2 | 2012 | 50 | 0.470 |
Why?
|
| Young Adult | 36 | 2021 | 22293 | 0.460 |
Why?
|
| Carcinosarcoma | 3 | 2024 | 145 | 0.460 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 16 | 2013 | 2478 | 0.460 |
Why?
|
| Cell Division | 27 | 2020 | 2657 | 0.460 |
Why?
|
| Cyclin D1 | 7 | 2009 | 591 | 0.460 |
Why?
|
| Alphapapillomavirus | 4 | 2021 | 172 | 0.460 |
Why?
|
| Carcinoma, Papillary, Follicular | 2 | 2010 | 27 | 0.450 |
Why?
|
| ras Proteins | 6 | 2012 | 804 | 0.450 |
Why?
|
| Disease-Free Survival | 44 | 2020 | 10267 | 0.450 |
Why?
|
| Telomerase | 6 | 2015 | 544 | 0.440 |
Why?
|
| Apoptosis | 34 | 2017 | 7755 | 0.440 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 129 | 0.440 |
Why?
|
| DNA Primers | 15 | 2014 | 1492 | 0.440 |
Why?
|
| Sarcoma | 13 | 2020 | 1851 | 0.430 |
Why?
|
| Neoplasms | 26 | 2019 | 15933 | 0.430 |
Why?
|
| Survival Rate | 55 | 2020 | 12535 | 0.430 |
Why?
|
| Cisplatin | 13 | 2023 | 2499 | 0.430 |
Why?
|
| Mice | 68 | 2024 | 35477 | 0.430 |
Why?
|
| Sublingual Gland Neoplasms | 1 | 2012 | 3 | 0.430 |
Why?
|
| Retrospective Studies | 90 | 2024 | 39951 | 0.430 |
Why?
|
| Sebaceous Gland Neoplasms | 4 | 2006 | 100 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 11 | 8 | 2003 | 413 | 0.420 |
Why?
|
| MAP Kinase Signaling System | 5 | 2019 | 883 | 0.420 |
Why?
|
| Mutation, Missense | 11 | 2024 | 1197 | 0.420 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2009 | 69 | 0.420 |
Why?
|
| Gene Dosage | 10 | 2016 | 822 | 0.410 |
Why?
|
| Receptors, Notch | 4 | 2013 | 370 | 0.410 |
Why?
|
| Chromosomes, Human | 5 | 2017 | 288 | 0.410 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2013 | 659 | 0.410 |
Why?
|
| Transcriptional Activation | 5 | 2014 | 1107 | 0.410 |
Why?
|
| Carcinoma, Renal Cell | 17 | 2002 | 2387 | 0.410 |
Why?
|
| Combined Modality Therapy | 39 | 2020 | 9039 | 0.410 |
Why?
|
| Mesoderm | 4 | 2010 | 391 | 0.410 |
Why?
|
| Paranasal Sinus Diseases | 2 | 2020 | 33 | 0.400 |
Why?
|
| Animals | 86 | 2024 | 61554 | 0.400 |
Why?
|
| Cadherins | 6 | 2011 | 659 | 0.400 |
Why?
|
| Aicardi Syndrome | 1 | 2012 | 17 | 0.400 |
Why?
|
| Genetic Variation | 8 | 2015 | 2163 | 0.390 |
Why?
|
| Peripheral Nervous System Neoplasms | 2 | 2008 | 72 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 11 | 2012 | 1544 | 0.390 |
Why?
|
| Blotting, Western | 26 | 2013 | 3570 | 0.390 |
Why?
|
| MicroRNAs | 8 | 2020 | 2882 | 0.390 |
Why?
|
| Genes, p16 | 6 | 2016 | 132 | 0.390 |
Why?
|
| Lymph Nodes | 17 | 2020 | 3081 | 0.390 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 1341 | 0.380 |
Why?
|
| Ribonuclease III | 3 | 2019 | 182 | 0.380 |
Why?
|
| CpG Islands | 3 | 2015 | 669 | 0.380 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2012 | 667 | 0.380 |
Why?
|
| Cohort Studies | 20 | 2020 | 9478 | 0.370 |
Why?
|
| Retinoblastoma Protein | 5 | 1999 | 339 | 0.370 |
Why?
|
| Phenotype | 19 | 2017 | 6503 | 0.370 |
Why?
|
| Treatment Outcome | 56 | 2022 | 33807 | 0.370 |
Why?
|
| Radiotherapy, Adjuvant | 18 | 2020 | 2272 | 0.370 |
Why?
|
| Soft Tissue Neoplasms | 10 | 2005 | 930 | 0.360 |
Why?
|
| Carcinoma, Medullary | 6 | 2013 | 248 | 0.360 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2019 | 256 | 0.360 |
Why?
|
| Membrane Proteins | 5 | 2013 | 2922 | 0.360 |
Why?
|
| Bone Neoplasms | 10 | 2022 | 2674 | 0.360 |
Why?
|
| Nasopharyngeal Neoplasms | 4 | 2015 | 340 | 0.360 |
Why?
|
| Oncogene Fusion | 1 | 2010 | 62 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 20 | 2017 | 5775 | 0.350 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2015 | 1336 | 0.350 |
Why?
|
| Salivary Glands, Minor | 8 | 2012 | 36 | 0.350 |
Why?
|
| Adenocarcinoma, Sebaceous | 3 | 2006 | 66 | 0.350 |
Why?
|
| Gene Amplification | 12 | 2010 | 765 | 0.350 |
Why?
|
| Osteosarcoma | 6 | 2022 | 951 | 0.350 |
Why?
|
| Proteomics | 5 | 2021 | 1425 | 0.350 |
Why?
|
| Carcinoma, Ductal, Breast | 5 | 2005 | 1235 | 0.350 |
Why?
|
| Genes, myb | 3 | 2014 | 13 | 0.350 |
Why?
|
| Chromosome Mapping | 11 | 2013 | 1647 | 0.340 |
Why?
|
| Follow-Up Studies | 41 | 2020 | 15281 | 0.340 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 1275 | 0.340 |
Why?
|
| Lung Neoplasms | 26 | 2024 | 12040 | 0.340 |
Why?
|
| PTEN Phosphohydrolase | 9 | 2018 | 1008 | 0.340 |
Why?
|
| Polymorphism, Genetic | 9 | 2009 | 1557 | 0.340 |
Why?
|
| Repressor Proteins | 6 | 2019 | 1716 | 0.340 |
Why?
|
| Sarcoma, Synovial | 4 | 2004 | 141 | 0.340 |
Why?
|
| Plasmacytoma | 4 | 2002 | 125 | 0.340 |
Why?
|
| Parotid Gland | 4 | 2024 | 111 | 0.340 |
Why?
|
| Epithelium | 6 | 2008 | 786 | 0.330 |
Why?
|
| Smoking | 17 | 2015 | 2555 | 0.330 |
Why?
|
| Gene Deletion | 10 | 2018 | 1471 | 0.320 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2024 | 550 | 0.320 |
Why?
|
| Intestines | 1 | 2013 | 730 | 0.320 |
Why?
|
| Genomic Imprinting | 2 | 2000 | 198 | 0.320 |
Why?
|
| Receptors, Growth Factor | 2 | 2007 | 157 | 0.320 |
Why?
|
| Cetuximab | 8 | 2022 | 474 | 0.320 |
Why?
|
| Neoplasms, Squamous Cell | 4 | 2011 | 84 | 0.310 |
Why?
|
| Pyridines | 7 | 2011 | 1313 | 0.310 |
Why?
|
| Maxillary Sinus Neoplasms | 4 | 2020 | 114 | 0.310 |
Why?
|
| Teratocarcinoma | 1 | 2008 | 24 | 0.310 |
Why?
|
| Biopsy | 17 | 2017 | 3488 | 0.310 |
Why?
|
| Quinolones | 5 | 2018 | 163 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 6 | 2017 | 525 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2020 | 6258 | 0.300 |
Why?
|
| Benzenesulfonates | 4 | 2011 | 196 | 0.300 |
Why?
|
| Pathology | 1 | 2009 | 102 | 0.300 |
Why?
|
| Carcinogenesis | 6 | 2024 | 1034 | 0.300 |
Why?
|
| Receptors, Retinoic Acid | 6 | 2008 | 367 | 0.300 |
Why?
|
| Mice, Nude | 22 | 2017 | 4331 | 0.300 |
Why?
|
| Sensitivity and Specificity | 20 | 2011 | 5165 | 0.290 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2008 | 82 | 0.290 |
Why?
|
| Quinazolines | 5 | 2015 | 956 | 0.290 |
Why?
|
| Chemoradiotherapy | 7 | 2022 | 2028 | 0.290 |
Why?
|
| Receptor, IGF Type 1 | 5 | 2011 | 347 | 0.290 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2024 | 690 | 0.290 |
Why?
|
| Homeodomain Proteins | 3 | 2013 | 1124 | 0.290 |
Why?
|
| Risk Factors | 40 | 2020 | 17910 | 0.290 |
Why?
|
| Case-Control Studies | 27 | 2018 | 6240 | 0.290 |
Why?
|
| Genotype | 25 | 2015 | 4249 | 0.290 |
Why?
|
| Sequence Deletion | 4 | 2010 | 908 | 0.290 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2007 | 40 | 0.290 |
Why?
|
| Cell Cycle Proteins | 8 | 2011 | 2112 | 0.290 |
Why?
|
| Odontoma | 1 | 2006 | 3 | 0.280 |
Why?
|
| Collagen | 2 | 2009 | 723 | 0.280 |
Why?
|
| Receptor, trkC | 2 | 2012 | 23 | 0.280 |
Why?
|
| Maxillary Neoplasms | 1 | 2006 | 23 | 0.280 |
Why?
|
| Heterografts | 4 | 2017 | 738 | 0.270 |
Why?
|
| Microscopy, Confocal | 10 | 2011 | 660 | 0.270 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 3 | 2015 | 124 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 12 | 4 | 2000 | 197 | 0.270 |
Why?
|
| Fibrosarcoma | 2 | 2006 | 143 | 0.270 |
Why?
|
| RNA | 3 | 2004 | 1058 | 0.270 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2006 | 12 | 0.270 |
Why?
|
| DNA Repair | 9 | 2015 | 1906 | 0.270 |
Why?
|
| Diploidy | 12 | 1999 | 116 | 0.270 |
Why?
|
| Interphase | 6 | 1996 | 156 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 286 | 0.260 |
Why?
|
| src-Family Kinases | 2 | 2008 | 487 | 0.260 |
Why?
|
| Laryngectomy | 4 | 2016 | 244 | 0.260 |
Why?
|
| Fibroma | 3 | 1996 | 86 | 0.260 |
Why?
|
| Farnesyltranstransferase | 5 | 2011 | 125 | 0.260 |
Why?
|
| Ear, Middle | 2 | 2017 | 52 | 0.260 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2006 | 73 | 0.250 |
Why?
|
| Neoplasms, Second Primary | 6 | 2008 | 1388 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 17 | 8 | 2010 | 666 | 0.250 |
Why?
|
| S Phase | 8 | 2005 | 288 | 0.250 |
Why?
|
| Neck | 6 | 2017 | 395 | 0.250 |
Why?
|
| Neuroendocrine Tumors | 4 | 2018 | 656 | 0.250 |
Why?
|
| Mammary Neoplasms, Animal | 3 | 2024 | 236 | 0.250 |
Why?
|
| Transcriptome | 7 | 2024 | 1960 | 0.250 |
Why?
|
| Cell Differentiation | 12 | 2024 | 4105 | 0.250 |
Why?
|
| Cell Proliferation | 18 | 2019 | 7232 | 0.250 |
Why?
|
| Hemagglutinins | 3 | 2000 | 36 | 0.250 |
Why?
|
| Neurofibroma | 1 | 2005 | 31 | 0.250 |
Why?
|
| Nucleolus Organizer Region | 3 | 1994 | 19 | 0.240 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2020 | 57 | 0.240 |
Why?
|
| Ear Neoplasms | 2 | 2017 | 64 | 0.240 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2024 | 1385 | 0.240 |
Why?
|
| Neoplasms, Experimental | 5 | 2018 | 784 | 0.240 |
Why?
|
| Keratins | 13 | 2006 | 340 | 0.240 |
Why?
|
| Carcinogens | 7 | 2017 | 389 | 0.240 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2021 | 148 | 0.240 |
Why?
|
| DNA Mutational Analysis | 11 | 2017 | 2357 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 11 | 2023 | 4481 | 0.240 |
Why?
|
| Genomics | 9 | 2023 | 2832 | 0.240 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2009 | 334 | 0.240 |
Why?
|
| Cell Cycle | 16 | 2007 | 2135 | 0.240 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2023 | 3416 | 0.240 |
Why?
|
| Microscopy, Electron | 21 | 1999 | 703 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 9 | 2011 | 1586 | 0.230 |
Why?
|
| Myxoma | 2 | 1996 | 67 | 0.230 |
Why?
|
| Adenoviridae | 10 | 2003 | 1492 | 0.230 |
Why?
|
| Hemangiopericytoma | 4 | 1993 | 59 | 0.230 |
Why?
|
| Antigens, Differentiation | 3 | 2000 | 246 | 0.230 |
Why?
|
| Endolymphatic Sac | 2 | 1994 | 11 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2020 | 7786 | 0.230 |
Why?
|
| Heterozygote | 8 | 2007 | 1058 | 0.220 |
Why?
|
| Proportional Hazards Models | 14 | 2020 | 5102 | 0.220 |
Why?
|
| Genome, Human | 3 | 2015 | 1896 | 0.220 |
Why?
|
| Down-Regulation | 12 | 2010 | 2087 | 0.220 |
Why?
|
| Head | 3 | 2017 | 248 | 0.220 |
Why?
|
| Multivariate Analysis | 19 | 2020 | 4326 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2019 | 2359 | 0.220 |
Why?
|
| HIV Seropositivity | 2 | 2017 | 155 | 0.220 |
Why?
|
| Tumor Burden | 5 | 2024 | 2033 | 0.220 |
Why?
|
| Neoplasm, Residual | 7 | 2018 | 1761 | 0.220 |
Why?
|
| Exome | 4 | 2019 | 1249 | 0.220 |
Why?
|
| Child | 39 | 2020 | 30596 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 14 | 2011 | 5581 | 0.210 |
Why?
|
| Tumor Microenvironment | 8 | 2024 | 3041 | 0.210 |
Why?
|
| Maxillary Sinus | 2 | 2020 | 21 | 0.210 |
Why?
|
| Prospective Studies | 27 | 2023 | 13445 | 0.210 |
Why?
|
| Proliferating Cell Nuclear Antigen | 9 | 1996 | 198 | 0.210 |
Why?
|
| Pleural Neoplasms | 5 | 2007 | 485 | 0.210 |
Why?
|
| Nasal Cavity | 5 | 2020 | 155 | 0.210 |
Why?
|
| Proteogenomics | 2 | 2021 | 110 | 0.210 |
Why?
|
| Lymphoma | 10 | 2003 | 1516 | 0.210 |
Why?
|
| Genes, ras | 6 | 2017 | 678 | 0.210 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2013 | 1837 | 0.210 |
Why?
|
| Patient Selection | 4 | 2014 | 2032 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2022 | 84 | 0.200 |
Why?
|
| Anticarcinogenic Agents | 3 | 2016 | 368 | 0.200 |
Why?
|
| Microscopy, Fluorescence | 7 | 2009 | 768 | 0.200 |
Why?
|
| Respiratory Mucosa | 1 | 2003 | 212 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2019 | 98 | 0.200 |
Why?
|
| Leiomyosarcoma | 6 | 2007 | 253 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 7 | 4 | 2010 | 234 | 0.200 |
Why?
|
| Paraproteinemias | 1 | 2002 | 58 | 0.200 |
Why?
|
| Molecular Sequence Data | 20 | 2014 | 6655 | 0.200 |
Why?
|
| Phosphorylation | 17 | 2019 | 4906 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2023 | 1032 | 0.200 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2011 | 866 | 0.200 |
Why?
|
| Reproducibility of Results | 10 | 2015 | 6191 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 1999 | 230 | 0.190 |
Why?
|
| Pathology, Surgical | 1 | 2002 | 78 | 0.190 |
Why?
|
| Carcinoma, Basosquamous | 3 | 2008 | 13 | 0.190 |
Why?
|
| Time Factors | 16 | 2024 | 12990 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 2395 | 0.190 |
Why?
|
| Cluster Analysis | 6 | 2015 | 1075 | 0.190 |
Why?
|
| Muscle Proteins | 2 | 2007 | 485 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2003 | 155 | 0.190 |
Why?
|
| Carrier Proteins | 7 | 2010 | 2085 | 0.190 |
Why?
|
| Age Factors | 17 | 2018 | 5458 | 0.190 |
Why?
|
| Immunotherapy | 4 | 2021 | 3559 | 0.190 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 133 | 0.190 |
Why?
|
| Disease Models, Animal | 12 | 2020 | 7320 | 0.190 |
Why?
|
| Gene Rearrangement | 5 | 2019 | 811 | 0.190 |
Why?
|
| Paclitaxel | 11 | 2011 | 2105 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2002 | 257 | 0.180 |
Why?
|
| Wound Healing | 3 | 2012 | 770 | 0.180 |
Why?
|
| Piperidines | 4 | 2008 | 1099 | 0.180 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2006 | 111 | 0.180 |
Why?
|
| Genes, Neoplasm | 4 | 2014 | 314 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 5 | 4 | 1999 | 275 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 1999 | 150 | 0.180 |
Why?
|
| Alleles | 10 | 2018 | 2597 | 0.180 |
Why?
|
| DNA, Mitochondrial | 2 | 2014 | 311 | 0.180 |
Why?
|
| Kidney Cortex | 2 | 1997 | 31 | 0.180 |
Why?
|
| Skull Base | 2 | 2020 | 225 | 0.180 |
Why?
|
| Vocal Cords | 2 | 2018 | 106 | 0.180 |
Why?
|
| In Situ Hybridization | 9 | 2013 | 1044 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-ret | 5 | 2011 | 375 | 0.180 |
Why?
|
| Testicular Neoplasms | 7 | 1997 | 560 | 0.180 |
Why?
|
| Amino Acid Substitution | 6 | 2018 | 656 | 0.170 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2010 | 585 | 0.170 |
Why?
|
| Serrate-Jagged Proteins | 2 | 2013 | 85 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2006 | 155 | 0.170 |
Why?
|
| Adrenergic Neurons | 1 | 2020 | 12 | 0.170 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2013 | 688 | 0.170 |
Why?
|
| Nephroma, Mesoblastic | 1 | 1999 | 14 | 0.170 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 8 | 2003 | 192 | 0.170 |
Why?
|
| Protein Isoforms | 3 | 2011 | 843 | 0.170 |
Why?
|
| Jagged-1 Protein | 2 | 2013 | 102 | 0.170 |
Why?
|
| DNA Damage | 9 | 2016 | 1990 | 0.170 |
Why?
|
| Choristoma | 3 | 1996 | 81 | 0.170 |
Why?
|
| Phyllodes Tumor | 2 | 1990 | 64 | 0.170 |
Why?
|
| Homozygote | 2 | 2018 | 772 | 0.170 |
Why?
|
| Cyclooxygenase 2 | 3 | 2011 | 494 | 0.170 |
Why?
|
| Spectrum Analysis | 3 | 2009 | 144 | 0.170 |
Why?
|
| History, 20th Century | 2 | 2014 | 545 | 0.170 |
Why?
|
| Bacteria | 1 | 2024 | 652 | 0.170 |
Why?
|
| Co-Repressor Proteins | 4 | 2007 | 120 | 0.170 |
Why?
|
| DNA Copy Number Variations | 4 | 2014 | 1576 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2012 | 537 | 0.170 |
Why?
|
| Hormone Antagonists | 1 | 2019 | 115 | 0.170 |
Why?
|
| Oropharynx | 2 | 2003 | 80 | 0.170 |
Why?
|
| Oncogene Proteins v-myb | 2 | 2016 | 8 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 3 | 1997 | 426 | 0.160 |
Why?
|
| Early Detection of Cancer | 5 | 2011 | 1344 | 0.160 |
Why?
|
| Serine Proteinase Inhibitors | 3 | 2004 | 59 | 0.160 |
Why?
|
| Cell Transdifferentiation | 1 | 2020 | 114 | 0.160 |
Why?
|
| PAX8 Transcription Factor | 1 | 2019 | 51 | 0.160 |
Why?
|
| Li-Fraumeni Syndrome | 2 | 2014 | 166 | 0.160 |
Why?
|
| Point Mutation | 5 | 2013 | 788 | 0.160 |
Why?
|
| Neuritis | 1 | 2018 | 5 | 0.160 |
Why?
|
| Retinoids | 2 | 2018 | 152 | 0.160 |
Why?
|
| Desmin | 6 | 2009 | 61 | 0.160 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2017 | 442 | 0.160 |
Why?
|
| Predictive Value of Tests | 14 | 2017 | 4966 | 0.160 |
Why?
|
| Cytokines | 6 | 2012 | 2805 | 0.160 |
Why?
|
| Lymphocytes | 7 | 2018 | 1273 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2008 | 677 | 0.160 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2016 | 2178 | 0.160 |
Why?
|
| Genes, Retinoblastoma | 2 | 2002 | 92 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 2 | 1992 | 381 | 0.160 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1998 | 40 | 0.150 |
Why?
|
| Sensory Receptor Cells | 1 | 2020 | 157 | 0.150 |
Why?
|
| Deubiquitinating Enzyme CYLD | 1 | 2018 | 22 | 0.150 |
Why?
|
| Blotting, Southern | 9 | 1998 | 454 | 0.150 |
Why?
|
| Granuloma | 2 | 2018 | 152 | 0.150 |
Why?
|
| Terminology as Topic | 3 | 2016 | 417 | 0.150 |
Why?
|
| Palatal Neoplasms | 3 | 1997 | 27 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2001 | 1068 | 0.150 |
Why?
|
| Hyperplasia | 8 | 2009 | 571 | 0.150 |
Why?
|
| Colonic Neoplasms | 6 | 2003 | 1437 | 0.150 |
Why?
|
| Hypopharyngeal Neoplasms | 5 | 2017 | 84 | 0.150 |
Why?
|
| Child, Preschool | 14 | 2020 | 17095 | 0.150 |
Why?
|
| Tissue Array Analysis | 5 | 2015 | 757 | 0.150 |
Why?
|
| Oncogenes | 5 | 2013 | 698 | 0.150 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2017 | 12 | 0.150 |
Why?
|
| E2F6 Transcription Factor | 1 | 2017 | 10 | 0.150 |
Why?
|
| Cell Movement | 8 | 2011 | 2468 | 0.150 |
Why?
|
| Sinusitis | 2 | 1996 | 148 | 0.150 |
Why?
|
| Recurrence | 9 | 2020 | 4880 | 0.150 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 2 | 2008 | 65 | 0.150 |
Why?
|
| DNA Adducts | 2 | 2010 | 214 | 0.150 |
Why?
|
| Acridine Orange | 3 | 1995 | 10 | 0.150 |
Why?
|
| Otorhinolaryngologic Neoplasms | 2 | 1999 | 22 | 0.150 |
Why?
|
| RNA, Untranslated | 1 | 1999 | 242 | 0.150 |
Why?
|
| Chromosome Disorders | 3 | 1997 | 420 | 0.150 |
Why?
|
| Books | 1 | 2017 | 7 | 0.150 |
Why?
|
| Cellular Reprogramming | 1 | 2020 | 203 | 0.150 |
Why?
|
| Tumor Virus Infections | 3 | 2010 | 248 | 0.150 |
Why?
|
| Isotretinoin | 8 | 2011 | 161 | 0.150 |
Why?
|
| Incidence | 8 | 2020 | 5841 | 0.150 |
Why?
|
| Proteome | 2 | 2016 | 570 | 0.150 |
Why?
|
| Tumor Protein p73 | 5 | 2008 | 114 | 0.150 |
Why?
|
| Cytoplasm | 7 | 2007 | 702 | 0.150 |
Why?
|
| Genetic Therapy | 8 | 2003 | 1715 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 12 | 2019 | 7054 | 0.140 |
Why?
|
| Diagnostic Imaging | 3 | 2010 | 1173 | 0.140 |
Why?
|
| Radiation Tolerance | 2 | 2016 | 639 | 0.140 |
Why?
|
| Exons | 7 | 2011 | 1390 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1582 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 841 | 0.140 |
Why?
|
| Sex Factors | 9 | 2017 | 2186 | 0.140 |
Why?
|
| Fenretinide | 2 | 2009 | 100 | 0.140 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2018 | 1536 | 0.140 |
Why?
|
| Trisomy | 2 | 1996 | 240 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 6 | 2021 | 5238 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 2 | 2010 | 354 | 0.140 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2017 | 74 | 0.140 |
Why?
|
| Ovarian Neoplasms | 10 | 2001 | 4796 | 0.140 |
Why?
|
| DNA Modification Methylases | 2 | 2008 | 176 | 0.140 |
Why?
|
| Genome, Mitochondrial | 2 | 2014 | 40 | 0.140 |
Why?
|
| Risk Assessment | 9 | 2018 | 6779 | 0.140 |
Why?
|
| Diagnostic Errors | 2 | 2020 | 518 | 0.140 |
Why?
|
| Mesothelioma | 3 | 2007 | 558 | 0.140 |
Why?
|
| Odontogenic Tumors | 1 | 1996 | 6 | 0.140 |
Why?
|
| Genes, erbB-2 | 5 | 1999 | 227 | 0.140 |
Why?
|
| Neurilemmoma | 1 | 2017 | 137 | 0.140 |
Why?
|
| Teratoma | 5 | 2002 | 248 | 0.140 |
Why?
|
| Oncogene Proteins | 2 | 1995 | 367 | 0.140 |
Why?
|
| Lacrimal Apparatus | 1 | 2018 | 185 | 0.130 |
Why?
|
| RNA, Small Interfering | 5 | 2011 | 2189 | 0.130 |
Why?
|
| Chromosomal Instability | 3 | 2008 | 228 | 0.130 |
Why?
|
| Evaluation Studies as Topic | 5 | 2007 | 451 | 0.130 |
Why?
|
| Nasal Polyps | 1 | 1996 | 29 | 0.130 |
Why?
|
| Cyclin B | 3 | 2002 | 69 | 0.130 |
Why?
|
| Medical Overuse | 1 | 2016 | 51 | 0.130 |
Why?
|
| Protein Transport | 3 | 2014 | 737 | 0.130 |
Why?
|
| DNA Glycosylases | 2 | 2008 | 88 | 0.130 |
Why?
|
| Codon | 5 | 2008 | 261 | 0.130 |
Why?
|
| Pharyngeal Neoplasms | 3 | 2012 | 142 | 0.130 |
Why?
|
| DNA Repair Enzymes | 2 | 2008 | 238 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 291 | 0.130 |
Why?
|
| Guideline Adherence | 2 | 2010 | 630 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2016 | 4965 | 0.130 |
Why?
|
| Texas | 10 | 2016 | 6452 | 0.130 |
Why?
|
| Phylogeny | 2 | 2017 | 860 | 0.130 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 1996 | 98 | 0.130 |
Why?
|
| Chromosome Breakpoints | 1 | 2015 | 102 | 0.130 |
Why?
|
| Spectrometry, Fluorescence | 3 | 2008 | 206 | 0.130 |
Why?
|
| Gene Order | 1 | 2015 | 107 | 0.130 |
Why?
|
| Culture Media, Serum-Free | 2 | 2014 | 79 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 238 | 0.130 |
Why?
|
| DNA, Satellite | 1 | 1995 | 44 | 0.130 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 116 | 0.130 |
Why?
|
| Thyroid Nodule | 1 | 2016 | 92 | 0.130 |
Why?
|
| Epithelial Cells | 5 | 2010 | 1877 | 0.130 |
Why?
|
| Microfilament Proteins | 2 | 2009 | 491 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2011 | 1270 | 0.130 |
Why?
|
| Adrenal Cortex Neoplasms | 3 | 1995 | 242 | 0.130 |
Why?
|
| Hip Joint | 1 | 2015 | 58 | 0.130 |
Why?
|
| Chymotrypsin | 2 | 2013 | 37 | 0.130 |
Why?
|
| Cytogenetic Analysis | 1 | 2017 | 574 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2008 | 1123 | 0.130 |
Why?
|
| Forecasting | 4 | 2013 | 702 | 0.120 |
Why?
|
| Cytogenetics | 1 | 1995 | 152 | 0.120 |
Why?
|
| Benzamides | 2 | 2019 | 1879 | 0.120 |
Why?
|
| Chloride Channels | 1 | 2015 | 77 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 719 | 0.120 |
Why?
|
| Joint Diseases | 1 | 2015 | 71 | 0.120 |
Why?
|
| Tetrazoles | 2 | 2006 | 95 | 0.120 |
Why?
|
| Genes, Dominant | 3 | 2011 | 356 | 0.120 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2015 | 78 | 0.120 |
Why?
|
| Basigin | 1 | 2015 | 22 | 0.120 |
Why?
|
| Ascitic Fluid | 2 | 1995 | 84 | 0.120 |
Why?
|
| Early Diagnosis | 2 | 2014 | 315 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2020 | 4006 | 0.120 |
Why?
|
| Purines | 2 | 2006 | 271 | 0.120 |
Why?
|
| Abdominal Neoplasms | 2 | 1995 | 251 | 0.120 |
Why?
|
| Nitriles | 1 | 2019 | 939 | 0.120 |
Why?
|
| Actins | 5 | 2009 | 586 | 0.120 |
Why?
|
| Phospholipases A2, Calcium-Independent | 1 | 2014 | 19 | 0.120 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2006 | 127 | 0.120 |
Why?
|
| Diagnostic Techniques and Procedures | 2 | 2011 | 50 | 0.120 |
Why?
|
| Antigens, Neoplasm | 6 | 1996 | 1581 | 0.120 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 1997 | 1000 | 0.120 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 398 | 0.120 |
Why?
|
| Glossectomy | 3 | 2011 | 43 | 0.120 |
Why?
|
| Fasciitis | 1 | 1994 | 39 | 0.120 |
Why?
|
| Re-Irradiation | 1 | 2016 | 166 | 0.120 |
Why?
|
| In Situ Nick-End Labeling | 6 | 2008 | 437 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 4 | 2015 | 2571 | 0.120 |
Why?
|
| Integrin alphaV | 1 | 2014 | 24 | 0.120 |
Why?
|
| Image Enhancement | 2 | 2010 | 553 | 0.120 |
Why?
|
| Epigenomics | 1 | 2015 | 272 | 0.110 |
Why?
|
| Subtilisins | 2 | 2004 | 17 | 0.110 |
Why?
|
| Tamoxifen | 1 | 2018 | 875 | 0.110 |
Why?
|
| Doxorubicin | 5 | 2012 | 3146 | 0.110 |
Why?
|
| Alcohol Drinking | 6 | 2013 | 600 | 0.110 |
Why?
|
| HMGA2 Protein | 1 | 2013 | 20 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 1998 | 966 | 0.110 |
Why?
|
| Chemotactic Factors | 3 | 2004 | 40 | 0.110 |
Why?
|
| Gene Frequency | 6 | 2018 | 1247 | 0.110 |
Why?
|
| Carcinoma in Situ | 2 | 1999 | 489 | 0.110 |
Why?
|
| Caspase 8 | 2 | 2013 | 146 | 0.110 |
Why?
|
| Rare Diseases | 2 | 2013 | 360 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 627 | 0.110 |
Why?
|
| Ipilimumab | 1 | 2018 | 765 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 489 | 0.110 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2007 | 318 | 0.110 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 1993 | 49 | 0.110 |
Why?
|
| Fatal Outcome | 4 | 2011 | 821 | 0.110 |
Why?
|
| Kidney | 4 | 2005 | 2105 | 0.110 |
Why?
|
| Oncogene Protein v-akt | 3 | 2010 | 101 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2020 | 3924 | 0.110 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2010 | 101 | 0.110 |
Why?
|
| Laryngeal Diseases | 2 | 2009 | 54 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2015 | 7899 | 0.110 |
Why?
|
| Cystic Fibrosis | 1 | 1996 | 291 | 0.110 |
Why?
|
| Rhinosporidiosis | 1 | 1992 | 1 | 0.110 |
Why?
|
| Rhinoscleroma | 1 | 1992 | 5 | 0.110 |
Why?
|
| Cathepsins | 2 | 2003 | 56 | 0.110 |
Why?
|
| Dermatofibrosarcoma | 1 | 2013 | 73 | 0.110 |
Why?
|
| Neurotrophin 3 | 1 | 2012 | 18 | 0.110 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2008 | 160 | 0.110 |
Why?
|
| Fluorescent Dyes | 2 | 2006 | 464 | 0.110 |
Why?
|
| Aging | 2 | 2018 | 1531 | 0.100 |
Why?
|
| Eosinophilia | 1 | 2015 | 184 | 0.100 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2015 | 327 | 0.100 |
Why?
|
| Deglutition Disorders | 2 | 2015 | 488 | 0.100 |
Why?
|
| Acid Anhydride Hydrolases | 2 | 2004 | 84 | 0.100 |
Why?
|
| Alternative Splicing | 2 | 2014 | 610 | 0.100 |
Why?
|
| Staining and Labeling | 12 | 2004 | 443 | 0.100 |
Why?
|
| Giant Cells | 1 | 1993 | 73 | 0.100 |
Why?
|
| Rhabdoid Tumor | 2 | 2004 | 106 | 0.100 |
Why?
|
| Carcinoma, Basal Cell | 5 | 2007 | 290 | 0.100 |
Why?
|
| Enzyme Activation | 4 | 2010 | 1801 | 0.100 |
Why?
|
| Parathyroid Neoplasms | 2 | 2004 | 190 | 0.100 |
Why?
|
| Epidermal Growth Factor | 6 | 2009 | 439 | 0.100 |
Why?
|
| Sarcoma, Ewing | 1 | 1996 | 428 | 0.100 |
Why?
|
| Chromosome Banding | 3 | 1999 | 280 | 0.100 |
Why?
|
| Chemokines, CXC | 2 | 2004 | 124 | 0.100 |
Why?
|
| Vestibular Diseases | 1 | 1993 | 69 | 0.100 |
Why?
|
| RNA, Long Noncoding | 2 | 2013 | 617 | 0.100 |
Why?
|
| S100 Proteins | 7 | 2008 | 184 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2018 | 5417 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 303 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2009 | 1430 | 0.100 |
Why?
|
| Pleural Effusion | 1 | 1994 | 228 | 0.100 |
Why?
|
| Osteoclasts | 1 | 1993 | 160 | 0.100 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 1992 | 346 | 0.100 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2011 | 23 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2015 | 517 | 0.100 |
Why?
|
| Neoplasm Transplantation | 8 | 2014 | 1552 | 0.100 |
Why?
|
| Genes, Developmental | 1 | 2011 | 11 | 0.100 |
Why?
|
| Artificial Gene Fusion | 2 | 2003 | 20 | 0.100 |
Why?
|
| bcl-2-Associated X Protein | 4 | 2007 | 374 | 0.100 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2011 | 62 | 0.100 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2015 | 291 | 0.100 |
Why?
|
| Genome-Wide Association Study | 3 | 2019 | 2346 | 0.100 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2000 | 176 | 0.100 |
Why?
|
| Adenofibroma | 2 | 1990 | 20 | 0.100 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2011 | 99 | 0.100 |
Why?
|
| Wilms Tumor | 1 | 1994 | 301 | 0.100 |
Why?
|
| Immunophenotyping | 5 | 2016 | 1725 | 0.100 |
Why?
|
| Serpins | 2 | 2003 | 72 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 5 | 2012 | 469 | 0.090 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 238 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1338 | 0.090 |
Why?
|
| Ultraviolet Rays | 4 | 2017 | 588 | 0.090 |
Why?
|
| Genetic Vectors | 8 | 2003 | 1847 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 481 | 0.090 |
Why?
|
| Anthracenes | 1 | 2011 | 47 | 0.090 |
Why?
|
| Cell Nucleus | 8 | 2007 | 1715 | 0.090 |
Why?
|
| Pyrimidines | 3 | 2010 | 3671 | 0.090 |
Why?
|
| F-Box Proteins | 1 | 2011 | 96 | 0.090 |
Why?
|
| Gene Transfer Techniques | 6 | 2003 | 800 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1095 | 0.090 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2010 | 28 | 0.090 |
Why?
|
| Fiber Optic Technology | 2 | 2009 | 146 | 0.090 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2010 | 31 | 0.090 |
Why?
|
| Bronchial Neoplasms | 1 | 1991 | 82 | 0.090 |
Why?
|
| Phosphoric Monoester Hydrolases | 3 | 2002 | 264 | 0.090 |
Why?
|
| Human papillomavirus 18 | 1 | 2010 | 42 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2003 | 1692 | 0.090 |
Why?
|
| RNA, Double-Stranded | 1 | 1991 | 106 | 0.090 |
Why?
|
| Carboplatin | 5 | 2015 | 880 | 0.090 |
Why?
|
| STAT5 Transcription Factor | 1 | 2011 | 226 | 0.090 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2010 | 34 | 0.090 |
Why?
|
| Mammography | 2 | 1996 | 1053 | 0.090 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2010 | 63 | 0.090 |
Why?
|
| Gingival Neoplasms | 2 | 2003 | 6 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2003 | 108 | 0.090 |
Why?
|
| Liver Neoplasms | 5 | 2016 | 4826 | 0.090 |
Why?
|
| Mitotic Index | 6 | 1999 | 162 | 0.090 |
Why?
|
| Stilbenes | 2 | 2007 | 86 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2007 | 1942 | 0.090 |
Why?
|
| Family Health | 1 | 2011 | 347 | 0.090 |
Why?
|
| Colon | 2 | 2009 | 684 | 0.090 |
Why?
|
| Contrast Media | 2 | 2007 | 1500 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1403 | 0.090 |
Why?
|
| Death-Associated Protein Kinases | 2 | 2006 | 22 | 0.090 |
Why?
|
| Pattern Recognition, Automated | 1 | 2010 | 120 | 0.090 |
Why?
|
| Genetic Association Studies | 4 | 2015 | 1098 | 0.090 |
Why?
|
| Receptor, trkB | 1 | 2010 | 52 | 0.090 |
Why?
|
| Interferon Type I | 2 | 2002 | 282 | 0.090 |
Why?
|
| Autoantibodies | 1 | 1993 | 605 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2009 | 622 | 0.090 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2010 | 105 | 0.090 |
Why?
|
| Mouth | 2 | 2009 | 125 | 0.090 |
Why?
|
| Baculoviridae | 3 | 2004 | 109 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2009 | 898 | 0.090 |
Why?
|
| Biomarkers | 8 | 2018 | 5054 | 0.090 |
Why?
|
| Tea | 1 | 2009 | 46 | 0.090 |
Why?
|
| Histiocytoma, Benign Fibrous | 2 | 1990 | 74 | 0.080 |
Why?
|
| Radiotherapy Dosage | 8 | 2017 | 4020 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2010 | 120 | 0.080 |
Why?
|
| Mice, Knockout | 9 | 2012 | 5692 | 0.080 |
Why?
|
| Cysts | 1 | 1991 | 206 | 0.080 |
Why?
|
| 4-Chloro-7-nitrobenzofurazan | 1 | 2009 | 9 | 0.080 |
Why?
|
| Remission Induction | 7 | 2015 | 3657 | 0.080 |
Why?
|
| HEK293 Cells | 3 | 2018 | 1459 | 0.080 |
Why?
|
| Stomatitis | 1 | 2010 | 193 | 0.080 |
Why?
|
| Transfection | 7 | 2016 | 3110 | 0.080 |
Why?
|
| Intermediate Filament Proteins | 2 | 2003 | 80 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 2403 | 0.080 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2009 | 71 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2009 | 101 | 0.080 |
Why?
|
| United States | 6 | 2020 | 15889 | 0.080 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2018 | 529 | 0.080 |
Why?
|
| Mass Spectrometry | 2 | 2013 | 722 | 0.080 |
Why?
|
| Deoxyglucose | 1 | 2009 | 119 | 0.080 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2009 | 50 | 0.080 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2006 | 222 | 0.080 |
Why?
|
| DNA Replication | 6 | 2014 | 768 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2018 | 1384 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2008 | 266 | 0.080 |
Why?
|
| Ifosfamide | 4 | 2011 | 358 | 0.080 |
Why?
|
| Cranial Irradiation | 2 | 2008 | 321 | 0.080 |
Why?
|
| Quality of Life | 2 | 2016 | 4794 | 0.080 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2009 | 106 | 0.080 |
Why?
|
| Virus Integration | 2 | 2021 | 73 | 0.080 |
Why?
|
| DNA, Complementary | 4 | 2003 | 931 | 0.080 |
Why?
|
| Microscopy, Interference | 1 | 2008 | 16 | 0.080 |
Why?
|
| Chromatography, Liquid | 2 | 2007 | 353 | 0.080 |
Why?
|
| Cancer Care Facilities | 4 | 2016 | 907 | 0.080 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2006 | 172 | 0.080 |
Why?
|
| Trastuzumab | 3 | 2023 | 743 | 0.080 |
Why?
|
| Larynx | 2 | 2005 | 146 | 0.080 |
Why?
|
| Odds Ratio | 6 | 2015 | 2311 | 0.080 |
Why?
|
| Mutagens | 2 | 2007 | 189 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 3 | 2005 | 299 | 0.080 |
Why?
|
| Mandible | 1 | 2009 | 191 | 0.080 |
Why?
|
| Refractometry | 1 | 2008 | 15 | 0.080 |
Why?
|
| Miniaturization | 1 | 2008 | 48 | 0.080 |
Why?
|
| Rectal Neoplasms | 2 | 1997 | 1240 | 0.080 |
Why?
|
| Photometry | 1 | 2008 | 23 | 0.080 |
Why?
|
| Linear Models | 2 | 2008 | 1095 | 0.080 |
Why?
|
| Chi-Square Distribution | 5 | 2010 | 1310 | 0.080 |
Why?
|
| Open Reading Frames | 2 | 2007 | 275 | 0.080 |
Why?
|
| Risk | 6 | 2010 | 1937 | 0.080 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1824 | 0.080 |
Why?
|
| Cell Death | 3 | 2006 | 686 | 0.080 |
Why?
|
| 4-Nitroquinoline-1-oxide | 2 | 2018 | 41 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 2198 | 0.080 |
Why?
|
| Spectral Karyotyping | 1 | 2007 | 16 | 0.080 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2010 | 199 | 0.080 |
Why?
|
| Epithelioid Cells | 1 | 2008 | 45 | 0.080 |
Why?
|
| Immunity, Cellular | 4 | 2001 | 437 | 0.070 |
Why?
|
| Genetic Markers | 6 | 2007 | 1073 | 0.070 |
Why?
|
| Cell Line | 6 | 2015 | 5326 | 0.070 |
Why?
|
| Models, Biological | 4 | 2008 | 3189 | 0.070 |
Why?
|
| Transcription, Genetic | 6 | 2011 | 3330 | 0.070 |
Why?
|
| Radiotherapy | 5 | 2017 | 1858 | 0.070 |
Why?
|
| beta Catenin | 2 | 2011 | 689 | 0.070 |
Why?
|
| Keratin-20 | 2 | 2006 | 43 | 0.070 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 1 | 2007 | 96 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2004 | 527 | 0.070 |
Why?
|
| Phagosomes | 1 | 2007 | 72 | 0.070 |
Why?
|
| Benzopyrenes | 1 | 2007 | 11 | 0.070 |
Why?
|
| ADP Ribose Transferases | 1 | 2007 | 28 | 0.070 |
Why?
|
| Cell Survival | 5 | 2008 | 3058 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2009 | 220 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2007 | 597 | 0.070 |
Why?
|
| Sulfones | 1 | 2008 | 145 | 0.070 |
Why?
|
| General Surgery | 1 | 2011 | 334 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2011 | 359 | 0.070 |
Why?
|
| Intestinal Neoplasms | 1 | 1989 | 205 | 0.070 |
Why?
|
| Lysosomes | 2 | 2007 | 345 | 0.070 |
Why?
|
| Somatomedins | 1 | 2007 | 74 | 0.070 |
Why?
|
| Niacinamide | 4 | 2011 | 428 | 0.070 |
Why?
|
| Tomography, Optical Coherence | 3 | 2011 | 552 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2009 | 626 | 0.070 |
Why?
|
| Pilot Projects | 5 | 2021 | 2853 | 0.070 |
Why?
|
| Vimentin | 5 | 2004 | 252 | 0.070 |
Why?
|
| Amino Acid Sequence | 8 | 2008 | 4542 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 197 | 0.070 |
Why?
|
| Methylation | 2 | 2006 | 625 | 0.070 |
Why?
|
| Endopeptidases | 1 | 2008 | 229 | 0.070 |
Why?
|
| fas Receptor | 2 | 2006 | 197 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2009 | 420 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 153 | 0.070 |
Why?
|
| Pharynx | 1 | 2007 | 150 | 0.070 |
Why?
|
| Interferon-alpha | 5 | 2009 | 959 | 0.070 |
Why?
|
| Algorithms | 5 | 2010 | 3904 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 674 | 0.070 |
Why?
|
| Janus Kinase 2 | 1 | 2011 | 755 | 0.070 |
Why?
|
| Reference Values | 6 | 2009 | 1129 | 0.070 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 2004 | 275 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 1991 | 576 | 0.070 |
Why?
|
| Fluorescence | 4 | 2009 | 197 | 0.070 |
Why?
|
| Xerostomia | 1 | 2008 | 205 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 4 | 2010 | 1072 | 0.070 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2006 | 101 | 0.070 |
Why?
|
| Thyroidectomy | 2 | 2008 | 489 | 0.070 |
Why?
|
| Cells, Cultured | 8 | 2010 | 5662 | 0.070 |
Why?
|
| Leukoplakia, Hairy | 2 | 2013 | 5 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 5 | 2012 | 741 | 0.070 |
Why?
|
| Lichen Planus, Oral | 2 | 2013 | 9 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 1993 | 2433 | 0.070 |
Why?
|
| Thiazoles | 1 | 2010 | 727 | 0.070 |
Why?
|
| Disulfides | 2 | 2004 | 111 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2007 | 1630 | 0.070 |
Why?
|
| Muscles | 1 | 1987 | 443 | 0.070 |
Why?
|
| Histological Techniques | 2 | 1998 | 63 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 2017 | 2317 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 5055 | 0.070 |
Why?
|
| Schistosomiasis | 3 | 1982 | 65 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 1998 | 1956 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 1998 | 190 | 0.070 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 153 | 0.070 |
Why?
|
| Subtraction Technique | 2 | 2004 | 143 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 3 | 1992 | 863 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 494 | 0.070 |
Why?
|
| Keratinocytes | 4 | 2017 | 244 | 0.060 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2007 | 165 | 0.060 |
Why?
|
| Breast | 2 | 2009 | 1369 | 0.060 |
Why?
|
| Mucous Membrane | 3 | 2011 | 260 | 0.060 |
Why?
|
| Transplantation, Heterologous | 5 | 2007 | 1053 | 0.060 |
Why?
|
| Complement C5 | 3 | 1983 | 15 | 0.060 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2021 | 64 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 1233 | 0.060 |
Why?
|
| Retinoid X Receptors | 1 | 2005 | 85 | 0.060 |
Why?
|
| Phenylurea Compounds | 4 | 2011 | 600 | 0.060 |
Why?
|
| Endometrial Neoplasms | 3 | 2005 | 1385 | 0.060 |
Why?
|
| Caseins | 3 | 1983 | 75 | 0.060 |
Why?
|
| Chromones | 1 | 2005 | 121 | 0.060 |
Why?
|
| Galectin 1 | 3 | 2000 | 20 | 0.060 |
Why?
|
| Protein Sorting Signals | 1 | 2005 | 55 | 0.060 |
Why?
|
| Infant | 8 | 2011 | 14045 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 1132 | 0.060 |
Why?
|
| Gene Knock-In Techniques | 2 | 2018 | 183 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2016 | 3533 | 0.060 |
Why?
|
| Vitamin E | 3 | 2000 | 132 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2005 | 105 | 0.060 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2005 | 91 | 0.060 |
Why?
|
| Plasminogen Activators | 1 | 2004 | 55 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 210 | 0.060 |
Why?
|
| Ear, External | 1 | 2005 | 44 | 0.060 |
Why?
|
| Tubulin | 1 | 2005 | 202 | 0.060 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2005 | 206 | 0.060 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2005 | 179 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2004 | 26 | 0.060 |
Why?
|
| Ligands | 3 | 2017 | 1008 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 1987 | 593 | 0.060 |
Why?
|
| Autophagy | 2 | 2007 | 906 | 0.060 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2007 | 376 | 0.060 |
Why?
|
| Prostatic Neoplasms | 10 | 1997 | 5867 | 0.060 |
Why?
|
| DNA, Viral | 4 | 2010 | 755 | 0.060 |
Why?
|
| Granuloma, Plasma Cell | 2 | 1995 | 39 | 0.060 |
Why?
|
| Paraffin Embedding | 4 | 2007 | 223 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 539 | 0.060 |
Why?
|
| Mucositis | 2 | 2015 | 149 | 0.060 |
Why?
|
| Intracellular Membranes | 1 | 2004 | 115 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 2 | 2005 | 564 | 0.060 |
Why?
|
| Trypsin | 1 | 2004 | 156 | 0.060 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 1983 | 157 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 361 | 0.060 |
Why?
|
| STAT1 Transcription Factor | 3 | 2017 | 162 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2009 | 1739 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2005 | 631 | 0.060 |
Why?
|
| Keratin-7 | 1 | 2003 | 48 | 0.060 |
Why?
|
| Lymph Node Excision | 3 | 2009 | 2068 | 0.060 |
Why?
|
| Oligopeptides | 3 | 1997 | 450 | 0.060 |
Why?
|
| Mediastinal Cyst | 1 | 2004 | 21 | 0.060 |
Why?
|
| Galectin 3 | 3 | 2000 | 131 | 0.060 |
Why?
|
| Mouthwashes | 1 | 2003 | 42 | 0.060 |
Why?
|
| NF-kappa B | 2 | 2011 | 1555 | 0.060 |
Why?
|
| Nucleic Acids | 1 | 2004 | 44 | 0.060 |
Why?
|
| Temporal Bone | 1 | 2005 | 109 | 0.060 |
Why?
|
| Statistics, Nonparametric | 3 | 2015 | 986 | 0.060 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2005 | 142 | 0.060 |
Why?
|
| Logistic Models | 5 | 2017 | 3445 | 0.060 |
Why?
|
| RNA, Ribosomal | 1 | 2004 | 93 | 0.060 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2023 | 33 | 0.060 |
Why?
|
| RNA, Transfer | 1 | 2004 | 87 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 1118 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2004 | 241 | 0.050 |
Why?
|
| Fibrinolysin | 1 | 2003 | 25 | 0.050 |
Why?
|
| Pancreatic Elastase | 1 | 2003 | 35 | 0.050 |
Why?
|
| Morpholines | 1 | 2005 | 296 | 0.050 |
Why?
|
| Eyelid Neoplasms | 1 | 2005 | 193 | 0.050 |
Why?
|
| Glucose | 1 | 2009 | 1209 | 0.050 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2003 | 53 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 5 | 2004 | 1469 | 0.050 |
Why?
|
| Proteins | 3 | 2001 | 2029 | 0.050 |
Why?
|
| Ligases | 2 | 2002 | 81 | 0.050 |
Why?
|
| Endothelial Growth Factors | 2 | 2001 | 231 | 0.050 |
Why?
|
| Histone Deacetylases | 1 | 2005 | 362 | 0.050 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 1089 | 0.050 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2004 | 141 | 0.050 |
Why?
|
| Indoles | 1 | 2008 | 1029 | 0.050 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 69 | 0.050 |
Why?
|
| Lymphokines | 2 | 2001 | 313 | 0.050 |
Why?
|
| Chromogranins | 4 | 2006 | 87 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2017 | 751 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2005 | 327 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2010 | 1464 | 0.050 |
Why?
|
| B-Lymphocytes | 2 | 1996 | 1421 | 0.050 |
Why?
|
| Adenoma, Islet Cell | 1 | 2002 | 25 | 0.050 |
Why?
|
| Fibroblasts | 3 | 2004 | 1647 | 0.050 |
Why?
|
| Nevus | 1 | 2003 | 118 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2003 | 133 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2004 | 314 | 0.050 |
Why?
|
| Mass Screening | 2 | 2009 | 1554 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 1 | 2006 | 692 | 0.050 |
Why?
|
| Tuberculosis, Meningeal | 1 | 1982 | 35 | 0.050 |
Why?
|
| Administration, Oral | 3 | 2016 | 1606 | 0.050 |
Why?
|
| Metaphase | 3 | 2008 | 124 | 0.050 |
Why?
|
| Genes, myc | 2 | 2011 | 371 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 256 | 0.050 |
Why?
|
| N-Formylmethionine | 1 | 1981 | 1 | 0.050 |
Why?
|
| Mice, Transgenic | 5 | 2014 | 4202 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2009 | 1580 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 1989 | 1456 | 0.050 |
Why?
|
| Phosphopyruvate Hydratase | 3 | 2006 | 88 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 2004 | 310 | 0.050 |
Why?
|
| Muscle Neoplasms | 1 | 2002 | 108 | 0.050 |
Why?
|
| Valine | 2 | 2015 | 178 | 0.050 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2002 | 121 | 0.050 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2000 | 7 | 0.050 |
Why?
|
| Stomach Neoplasms | 2 | 1993 | 2338 | 0.050 |
Why?
|
| Carcinogens, Environmental | 1 | 2000 | 27 | 0.050 |
Why?
|
| Radon | 1 | 2000 | 14 | 0.050 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2000 | 49 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2000 | 61 | 0.040 |
Why?
|
| Methionine | 1 | 1981 | 170 | 0.040 |
Why?
|
| Viral Vaccines | 1 | 2003 | 361 | 0.040 |
Why?
|
| Spectrum Analysis, Raman | 2 | 2011 | 37 | 0.040 |
Why?
|
| Osteosarcoma, Juxtacortical | 1 | 2000 | 4 | 0.040 |
Why?
|
| Serine Peptidase Inhibitor Kazal-Type 5 | 3 | 2005 | 9 | 0.040 |
Why?
|
| Adrenergic Antagonists | 1 | 2020 | 19 | 0.040 |
Why?
|
| Burns | 1 | 2001 | 130 | 0.040 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 3 | 2005 | 25 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2004 | 823 | 0.040 |
Why?
|
| Nasolacrimal Duct | 1 | 2020 | 45 | 0.040 |
Why?
|
| Colorectal Neoplasms | 5 | 1996 | 3707 | 0.040 |
Why?
|
| Paraffin | 2 | 1998 | 13 | 0.040 |
Why?
|
| Software | 2 | 2005 | 1358 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 2428 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2007 | 1440 | 0.040 |
Why?
|
| Sarcoma, Experimental | 1 | 2000 | 68 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 1982 | 433 | 0.040 |
Why?
|
| Protein Kinases | 2 | 2007 | 889 | 0.040 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 1999 | 5 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2007 | 2177 | 0.040 |
Why?
|
| Receptors, Adrenergic | 1 | 2020 | 53 | 0.040 |
Why?
|
| Regression Analysis | 4 | 2011 | 1567 | 0.040 |
Why?
|
| Neurites | 1 | 2020 | 70 | 0.040 |
Why?
|
| T-Lymphocytes | 4 | 2010 | 3953 | 0.040 |
Why?
|
| Hypertension | 1 | 2009 | 1580 | 0.040 |
Why?
|
| Ileal Neoplasms | 2 | 1990 | 49 | 0.040 |
Why?
|
| Microcirculation | 1 | 2000 | 189 | 0.040 |
Why?
|
| Palliative Care | 2 | 2009 | 2175 | 0.040 |
Why?
|
| Structure-Activity Relationship | 3 | 2006 | 976 | 0.040 |
Why?
|
| Paraganglioma | 2 | 1992 | 200 | 0.040 |
Why?
|
| Monosomy | 1 | 1999 | 98 | 0.040 |
Why?
|
| Sarcoma, Clear Cell | 1 | 1999 | 43 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 119 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 4 | 2002 | 5263 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 1485 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2018 | 1355 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 2000 | 191 | 0.040 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 1999 | 27 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 3845 | 0.040 |
Why?
|
| Cicatrix | 1 | 2001 | 189 | 0.040 |
Why?
|
| Electrocoagulation | 1 | 1999 | 68 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 1999 | 291 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2008 | 1550 | 0.040 |
Why?
|
| Arteriovenous Malformations | 1 | 1999 | 66 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 1329 | 0.040 |
Why?
|
| Cytodiagnosis | 2 | 1998 | 201 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 1101 | 0.040 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2020 | 209 | 0.040 |
Why?
|
| Mice, Mutant Strains | 2 | 2014 | 650 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 1197 | 0.040 |
Why?
|
| Infant, Newborn | 6 | 2001 | 8709 | 0.040 |
Why?
|
| In Vitro Techniques | 3 | 2011 | 1699 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2004 | 629 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 2018 | 125 | 0.040 |
Why?
|
| Carcinogenicity Tests | 1 | 1998 | 69 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2008 | 1941 | 0.040 |
Why?
|
| Molecular Probe Techniques | 1 | 1998 | 46 | 0.040 |
Why?
|
| International Agencies | 1 | 2018 | 108 | 0.040 |
Why?
|
| Induction Chemotherapy | 2 | 2012 | 670 | 0.040 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2002 | 285 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 2018 | 79 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2004 | 1105 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 1462 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2011 | 590 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2019 | 376 | 0.040 |
Why?
|
| Morphogenesis | 2 | 2009 | 316 | 0.040 |
Why?
|
| Thalidomide | 1 | 2001 | 597 | 0.040 |
Why?
|
| Chromosome Inversion | 1 | 1999 | 197 | 0.040 |
Why?
|
| Glutathione Transferase | 2 | 2011 | 364 | 0.040 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 93 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2011 | 3155 | 0.040 |
Why?
|
| Tissue Distribution | 3 | 2009 | 920 | 0.040 |
Why?
|
| Placebos | 2 | 2009 | 442 | 0.040 |
Why?
|
| Hemangioma | 2 | 1990 | 160 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 1998 | 138 | 0.040 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 61 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 2 | 2010 | 216 | 0.040 |
Why?
|
| Lip Neoplasms | 2 | 2006 | 20 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2000 | 376 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2018 | 111 | 0.040 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2018 | 141 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 4 | 1994 | 1029 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2016 | 2582 | 0.040 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 2 | 2007 | 64 | 0.040 |
Why?
|
| Polyploidy | 1 | 1998 | 76 | 0.040 |
Why?
|
| Granzymes | 1 | 2017 | 94 | 0.040 |
Why?
|
| Mitosis | 3 | 2011 | 679 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1997 | 142 | 0.040 |
Why?
|
| Crystallins | 1 | 1997 | 30 | 0.040 |
Why?
|
| Coloring Agents | 1 | 1998 | 232 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2002 | 551 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2018 | 556 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1997 | 189 | 0.040 |
Why?
|
| Azacitidine | 1 | 2003 | 1218 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 1998 | 258 | 0.040 |
Why?
|
| Thyroglossal Cyst | 1 | 1996 | 14 | 0.040 |
Why?
|
| Tongue Diseases | 1 | 1996 | 19 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 197 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2001 | 986 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 1997 | 156 | 0.030 |
Why?
|
| Dental Papilla | 1 | 1996 | 1 | 0.030 |
Why?
|
| Dental Pulp | 1 | 1996 | 1 | 0.030 |
Why?
|
| Dental Sac | 1 | 1996 | 1 | 0.030 |
Why?
|
| Edema | 1 | 2018 | 263 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2018 | 279 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2018 | 265 | 0.030 |
Why?
|
| Leukemia P388 | 1 | 1996 | 28 | 0.030 |
Why?
|
| Monocytes | 2 | 2000 | 784 | 0.030 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2016 | 29 | 0.030 |
Why?
|
| Pelvic Exenteration | 1 | 1997 | 112 | 0.030 |
Why?
|
| Cyclin B1 | 3 | 2002 | 60 | 0.030 |
Why?
|
| Gene Products, tat | 1 | 1996 | 65 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1998 | 317 | 0.030 |
Why?
|
| Administration, Topical | 2 | 2009 | 263 | 0.030 |
Why?
|
| Histones | 1 | 2003 | 1512 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 2051 | 0.030 |
Why?
|
| alpha-Tocopherol | 2 | 2009 | 80 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2013 | 682 | 0.030 |
Why?
|
| Hemarthrosis | 1 | 2015 | 5 | 0.030 |
Why?
|
| Enthesopathy | 1 | 2015 | 3 | 0.030 |
Why?
|
| Mitochondria | 2 | 2014 | 1292 | 0.030 |
Why?
|
| Y Chromosome | 1 | 1996 | 78 | 0.030 |
Why?
|
| Egypt | 1 | 2015 | 45 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2013 | 498 | 0.030 |
Why?
|
| Binding Sites | 3 | 2007 | 2249 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2017 | 282 | 0.030 |
Why?
|
| Skin | 2 | 2017 | 1283 | 0.030 |
Why?
|
| Synovitis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Lung | 2 | 2024 | 3288 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 306 | 0.030 |
Why?
|
| Protein Array Analysis | 2 | 2011 | 503 | 0.030 |
Why?
|
| RNA, Antisense | 1 | 1995 | 78 | 0.030 |
Why?
|
| Spinal Cord | 1 | 1999 | 718 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 1996 | 188 | 0.030 |
Why?
|
| Plasma Cell Granuloma, Pulmonary | 1 | 1995 | 6 | 0.030 |
Why?
|
| Age Distribution | 2 | 2013 | 729 | 0.030 |
Why?
|
| Mesenteric Veins | 1 | 1996 | 83 | 0.030 |
Why?
|
| Dysgerminoma | 2 | 1992 | 42 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2017 | 315 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2001 | 1145 | 0.030 |
Why?
|
| Receptors, Odorant | 1 | 2015 | 47 | 0.030 |
Why?
|
| Pedigree | 3 | 2004 | 2041 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2014 | 1825 | 0.030 |
Why?
|
| Piperazines | 1 | 2004 | 2145 | 0.030 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2015 | 41 | 0.030 |
Why?
|
| Vocal Cord Dysfunction | 1 | 2015 | 17 | 0.030 |
Why?
|
| Genes, Viral | 1 | 1995 | 257 | 0.030 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2015 | 56 | 0.030 |
Why?
|
| Carcinoma, Skin Appendage | 1 | 1994 | 16 | 0.030 |
Why?
|
| Surveys and Questionnaires | 3 | 2013 | 5938 | 0.030 |
Why?
|
| Microdissection | 2 | 2005 | 85 | 0.030 |
Why?
|
| Keratoacanthoma | 1 | 1994 | 19 | 0.030 |
Why?
|
| Base Composition | 1 | 2014 | 92 | 0.030 |
Why?
|
| Clone Cells | 1 | 1996 | 590 | 0.030 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1997 | 296 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 2007 | 105 | 0.030 |
Why?
|
| Microtubules | 2 | 2007 | 329 | 0.030 |
Why?
|
| Computational Biology | 2 | 2014 | 1295 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2007 | 526 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 933 | 0.030 |
Why?
|
| Hypopharynx | 1 | 1994 | 22 | 0.030 |
Why?
|
| Granulosa Cell Tumor | 1 | 1995 | 81 | 0.030 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 1995 | 64 | 0.030 |
Why?
|
| Quinolines | 1 | 2018 | 402 | 0.030 |
Why?
|
| Telomere | 1 | 1998 | 546 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2015 | 120 | 0.030 |
Why?
|
| Introns | 2 | 2011 | 461 | 0.030 |
Why?
|
| Arthritis | 1 | 2015 | 147 | 0.030 |
Why?
|
| Pharyngeal Diseases | 1 | 1994 | 51 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 789 | 0.030 |
Why?
|
| Proto-Oncogenes | 2 | 1996 | 208 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2015 | 220 | 0.030 |
Why?
|
| Seminoma | 1 | 1994 | 86 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2008 | 631 | 0.030 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 1995 | 76 | 0.030 |
Why?
|
| Adrenal Cortex | 1 | 1994 | 37 | 0.030 |
Why?
|
| Hypersensitivity | 1 | 1996 | 216 | 0.030 |
Why?
|
| Data Mining | 1 | 2014 | 83 | 0.030 |
Why?
|
| Response Elements | 1 | 2014 | 192 | 0.030 |
Why?
|
| Adenoma, Oxyphilic | 1 | 1994 | 76 | 0.030 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2013 | 43 | 0.030 |
Why?
|
| Chromogranin A | 3 | 2006 | 67 | 0.030 |
Why?
|
| Calcinosis | 2 | 2003 | 426 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 3 | 2001 | 107 | 0.030 |
Why?
|
| Ear Diseases | 1 | 1994 | 24 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 247 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 3412 | 0.030 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 1993 | 40 | 0.030 |
Why?
|
| Nail Diseases | 1 | 1994 | 39 | 0.030 |
Why?
|
| Inflammation | 4 | 2009 | 2492 | 0.030 |
Why?
|
| Lasers | 2 | 2005 | 235 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 2015 | 205 | 0.030 |
Why?
|
| Southwestern United States | 1 | 2013 | 60 | 0.030 |
Why?
|
| Gene Ontology | 1 | 2013 | 80 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 1 | 1993 | 53 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 336 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 727 | 0.030 |
Why?
|
| Portal Vein | 1 | 1996 | 363 | 0.030 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2014 | 214 | 0.030 |
Why?
|
| Myositis | 1 | 1994 | 86 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 1171 | 0.030 |
Why?
|
| Spodoptera | 2 | 2003 | 81 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2013 | 170 | 0.030 |
Why?
|
| Hydrops Fetalis | 1 | 1993 | 75 | 0.030 |
Why?
|
| Salvage Therapy | 2 | 2016 | 2124 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2016 | 758 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2013 | 167 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1993 | 136 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2015 | 335 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 236 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 699 | 0.030 |
Why?
|
| Mycoses | 1 | 1996 | 393 | 0.030 |
Why?
|
| Chromosomes | 1 | 1993 | 325 | 0.030 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 1992 | 16 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 291 | 0.030 |
Why?
|
| Mesonephroma | 1 | 1992 | 17 | 0.030 |
Why?
|
| Thymus Neoplasms | 2 | 2001 | 416 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 896 | 0.030 |
Why?
|
| Cell Line, Transformed | 2 | 2003 | 427 | 0.030 |
Why?
|
| Crohn Disease | 1 | 1996 | 331 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 1571 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 368 | 0.030 |
Why?
|
| Macrophages | 1 | 2018 | 1333 | 0.030 |
Why?
|
| Silver Staining | 1 | 1992 | 12 | 0.030 |
Why?
|
| Esophageal Neoplasms | 2 | 1999 | 3240 | 0.030 |
Why?
|
| Wnt1 Protein | 1 | 2012 | 100 | 0.030 |
Why?
|
| Testosterone | 1 | 1997 | 638 | 0.030 |
Why?
|
| Granular Cell Tumor | 1 | 1992 | 22 | 0.030 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2012 | 144 | 0.020 |
Why?
|
| Registries | 2 | 2010 | 2221 | 0.020 |
Why?
|
| Drug Antagonism | 1 | 2011 | 33 | 0.020 |
Why?
|
| HIV-1 | 1 | 1996 | 638 | 0.020 |
Why?
|
| Interferon-Stimulated Gene Factor 3 | 2 | 2002 | 7 | 0.020 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 2 | 2002 | 7 | 0.020 |
Why?
|
| STAT2 Transcription Factor | 2 | 2002 | 5 | 0.020 |
Why?
|
| DNA Nucleotidylexotransferase | 2 | 2006 | 56 | 0.020 |
Why?
|
| Rheumatoid Nodule | 1 | 2011 | 6 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1993 | 453 | 0.020 |
Why?
|
| Hyoid Bone | 1 | 2011 | 8 | 0.020 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2011 | 80 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2015 | 364 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2015 | 368 | 0.020 |
Why?
|
| Kisspeptins | 1 | 2011 | 12 | 0.020 |
Why?
|
| Keratin-19 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Rats | 3 | 2007 | 6404 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 959 | 0.020 |
Why?
|
| Suppression, Genetic | 1 | 2011 | 70 | 0.020 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2011 | 48 | 0.020 |
Why?
|
| INDEL Mutation | 1 | 2011 | 114 | 0.020 |
Why?
|
| Peptides | 1 | 1997 | 1503 | 0.020 |
Why?
|
| Lymphadenitis | 1 | 1991 | 42 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 1023 | 0.020 |
Why?
|
| Giant Cell Tumors | 1 | 1990 | 33 | 0.020 |
Why?
|
| RNA Splicing Factors | 1 | 2011 | 151 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 1991 | 87 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 159 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2011 | 175 | 0.020 |
Why?
|
| Calcium Oxalate | 1 | 1990 | 28 | 0.020 |
Why?
|
| Blood Group Antigens | 1 | 1991 | 76 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2011 | 385 | 0.020 |
Why?
|
| Calcitonin | 1 | 1991 | 182 | 0.020 |
Why?
|
| Immunoblotting | 3 | 1997 | 888 | 0.020 |
Why?
|
| Teratogens | 1 | 2011 | 92 | 0.020 |
Why?
|
| Interleukin-8 | 2 | 2004 | 528 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2010 | 160 | 0.020 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2011 | 173 | 0.020 |
Why?
|
| Synaptophysin | 2 | 2006 | 83 | 0.020 |
Why?
|
| Chromatin | 1 | 2016 | 1044 | 0.020 |
Why?
|
| Organelles | 1 | 1990 | 43 | 0.020 |
Why?
|
| Stomach | 1 | 1993 | 402 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2001 | 246 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2005 | 617 | 0.020 |
Why?
|
| Endocrine System Diseases | 1 | 1990 | 89 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2011 | 336 | 0.020 |
Why?
|
| Photochemotherapy | 1 | 2011 | 116 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2014 | 866 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2002 | 2325 | 0.020 |
Why?
|
| Prostatic Hyperplasia | 1 | 1991 | 201 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 188 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 666 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 1997 | 930 | 0.020 |
Why?
|
| Chemoprevention | 2 | 2002 | 251 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 1994 | 427 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 1658 | 0.020 |
Why?
|
| NAD | 1 | 2009 | 87 | 0.020 |
Why?
|
| Jejunal Neoplasms | 1 | 1989 | 32 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2009 | 38 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2002 | 163 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 1991 | 329 | 0.020 |
Why?
|
| Biliary Tract Neoplasms | 1 | 1992 | 181 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2010 | 135 | 0.020 |
Why?
|
| Chemokines, C | 1 | 2009 | 11 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2012 | 443 | 0.020 |
Why?
|
| TRPP Cation Channels | 1 | 2009 | 7 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1994 | 2903 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2009 | 62 | 0.020 |
Why?
|
| Lymphocyte Activation | 4 | 2000 | 1719 | 0.020 |
Why?
|
| Tripartite Motif Proteins | 1 | 2009 | 46 | 0.020 |
Why?
|
| Peroxiredoxins | 1 | 2009 | 18 | 0.020 |
Why?
|
| Lipoma | 1 | 1990 | 93 | 0.020 |
Why?
|
| beta Carotene | 1 | 2009 | 73 | 0.020 |
Why?
|
| Leiomyoma | 1 | 1990 | 161 | 0.020 |
Why?
|
| Vitamin A | 1 | 2009 | 90 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 2990 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 353 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2001 | 2636 | 0.020 |
Why?
|
| Diterpenes | 1 | 2009 | 115 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2011 | 412 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2009 | 306 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2009 | 193 | 0.020 |
Why?
|
| Secretory Rate | 1 | 2008 | 16 | 0.020 |
Why?
|
| Genes, Suppressor | 1 | 2008 | 24 | 0.020 |
Why?
|
| Injections, Intralesional | 2 | 2000 | 169 | 0.020 |
Why?
|
| Salivation | 1 | 2008 | 23 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 2394 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 168 | 0.020 |
Why?
|
| Spleen | 2 | 1982 | 721 | 0.020 |
Why?
|
| Isoantigens | 2 | 2003 | 66 | 0.020 |
Why?
|
| Separase | 1 | 2008 | 32 | 0.020 |
Why?
|
| Pericardium | 1 | 1989 | 147 | 0.020 |
Why?
|
| Thymoma | 1 | 1992 | 252 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 434 | 0.020 |
Why?
|
| Chromatids | 1 | 2008 | 84 | 0.020 |
Why?
|
| Anaphase | 1 | 2008 | 54 | 0.020 |
Why?
|
| Gene Expression Regulation | 3 | 2006 | 4104 | 0.020 |
Why?
|
| Tobacco Products | 1 | 2010 | 157 | 0.020 |
Why?
|
| S100 Calcium Binding Protein A7 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2009 | 381 | 0.020 |
Why?
|
| Tetracycline | 1 | 2008 | 106 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2010 | 389 | 0.020 |
Why?
|
| G1 Phase | 1 | 2009 | 305 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 1104 | 0.020 |
Why?
|
| Nasal Obstruction | 1 | 2008 | 22 | 0.020 |
Why?
|
| Schistosoma mansoni | 2 | 1982 | 34 | 0.020 |
Why?
|
| Comet Assay | 1 | 2007 | 57 | 0.020 |
Why?
|
| Brain Neoplasms | 3 | 2003 | 4966 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2009 | 224 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 1379 | 0.020 |
Why?
|
| Aurora Kinase A | 1 | 2009 | 209 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2009 | 511 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 197 | 0.020 |
Why?
|
| Genital Neoplasms, Male | 1 | 1987 | 44 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2007 | 64 | 0.020 |
Why?
|
| Orbital Neoplasms | 1 | 1990 | 234 | 0.020 |
Why?
|
| Seminal Vesicles | 1 | 1987 | 149 | 0.020 |
Why?
|
| Prometaphase | 1 | 2007 | 2 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2010 | 518 | 0.020 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2007 | 88 | 0.020 |
Why?
|
| Heart Neoplasms | 1 | 1989 | 209 | 0.020 |
Why?
|
| Kinetochores | 1 | 2007 | 28 | 0.020 |
Why?
|
| Prostate | 2 | 1994 | 1089 | 0.020 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2007 | 27 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 67 | 0.020 |
Why?
|
| Crystallization | 2 | 1991 | 128 | 0.020 |
Why?
|
| Plasmids | 1 | 2009 | 927 | 0.020 |
Why?
|
| Artifacts | 1 | 2010 | 536 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2007 | 97 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2009 | 814 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2007 | 48 | 0.020 |
Why?
|
| Extremities | 1 | 1989 | 311 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2007 | 251 | 0.020 |
Why?
|
| Dimerization | 1 | 2007 | 310 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2007 | 111 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2007 | 204 | 0.020 |
Why?
|
| Dasatinib | 1 | 2010 | 881 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 1998 | 170 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2006 | 88 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 1999 | 720 | 0.020 |
Why?
|
| Amino Acids | 1 | 2009 | 746 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 1987 | 250 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 1003 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1991 | 690 | 0.020 |
Why?
|
| Radiography | 3 | 1998 | 1993 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 694 | 0.020 |
Why?
|
| rhoB GTP-Binding Protein | 1 | 2006 | 7 | 0.020 |
Why?
|
| Sirolimus | 1 | 2010 | 830 | 0.020 |
Why?
|
| Liver Diseases, Parasitic | 2 | 1979 | 4 | 0.020 |
Why?
|
| Chorioallantoic Membrane | 1 | 2006 | 25 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2007 | 494 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2006 | 117 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2013 | 2261 | 0.020 |
Why?
|
| Selection Bias | 1 | 2005 | 47 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 1075 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 597 | 0.020 |
Why?
|
| Osteitis | 1 | 2005 | 16 | 0.020 |
Why?
|
| Norway | 1 | 2005 | 42 | 0.020 |
Why?
|
| Cell Shape | 1 | 2005 | 126 | 0.020 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 2 | 1983 | 22 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2008 | 709 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2006 | 258 | 0.020 |
Why?
|
| Histone Deacetylase 6 | 1 | 2005 | 45 | 0.020 |
Why?
|
| Chickens | 1 | 2006 | 783 | 0.020 |
Why?
|
| HIV Infections | 1 | 2017 | 2158 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 82 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2005 | 254 | 0.020 |
Why?
|
| Temperature | 1 | 2006 | 537 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2004 | 94 | 0.010 |
Why?
|
| Hyperparathyroidism | 1 | 2005 | 101 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2006 | 608 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2006 | 561 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2004 | 66 | 0.010 |
Why?
|
| Genital Neoplasms, Female | 1 | 2011 | 794 | 0.010 |
Why?
|
| Streptavidin | 1 | 2004 | 13 | 0.010 |
Why?
|
| Vinculin | 1 | 2004 | 15 | 0.010 |
Why?
|
| Eyelids | 1 | 2005 | 156 | 0.010 |
Why?
|
| Fluorometry | 1 | 2004 | 35 | 0.010 |
Why?
|
| Insecta | 1 | 2004 | 87 | 0.010 |
Why?
|
| Protein Binding | 1 | 2010 | 3473 | 0.010 |
Why?
|
| Acetylation | 1 | 2005 | 516 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2004 | 348 | 0.010 |
Why?
|
| Proline | 1 | 2004 | 127 | 0.010 |
Why?
|
| Asbestosis | 1 | 2003 | 8 | 0.010 |
Why?
|
| alpha-Amylases | 1 | 2003 | 15 | 0.010 |
Why?
|
| Cotinine | 1 | 2003 | 42 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2003 | 24 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 2004 | 145 | 0.010 |
Why?
|
| Trypsin Inhibitors | 1 | 2003 | 19 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 617 | 0.010 |
Why?
|
| Germ Cells | 1 | 2005 | 329 | 0.010 |
Why?
|
| p21-Activated Kinases | 1 | 2004 | 131 | 0.010 |
Why?
|
| Cathepsin G | 1 | 2003 | 22 | 0.010 |
Why?
|
| Jagged-2 Protein | 1 | 2003 | 12 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2003 | 21 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 1016 | 0.010 |
Why?
|
| Cathepsin K | 1 | 2003 | 15 | 0.010 |
Why?
|
| Face | 1 | 2005 | 252 | 0.010 |
Why?
|
| Cathepsin L | 1 | 2003 | 31 | 0.010 |
Why?
|
| Transcription Factor HES-1 | 1 | 2003 | 47 | 0.010 |
Why?
|
| Laryngoscopy | 1 | 2005 | 200 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2008 | 1572 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2002 | 2663 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 183 | 0.010 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2003 | 57 | 0.010 |
Why?
|
| Cytoplasmic Granules | 2 | 1993 | 85 | 0.010 |
Why?
|
| Ovum | 1 | 1982 | 36 | 0.010 |
Why?
|
| Taxoids | 1 | 2006 | 1019 | 0.010 |
Why?
|
| Rosette Formation | 1 | 1982 | 38 | 0.010 |
Why?
|
| Tuberculin | 1 | 1982 | 21 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2008 | 1330 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2008 | 1185 | 0.010 |
Why?
|
| Haplotypes | 1 | 2005 | 909 | 0.010 |
Why?
|
| Granulocytes | 1 | 2003 | 244 | 0.010 |
Why?
|
| Keratosis | 1 | 2002 | 38 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2004 | 293 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 206 | 0.010 |
Why?
|
| Parathyroidectomy | 1 | 2004 | 211 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 714 | 0.010 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 1982 | 37 | 0.010 |
Why?
|
| Pleura | 1 | 2003 | 130 | 0.010 |
Why?
|
| Cyclin D | 1 | 2001 | 39 | 0.010 |
Why?
|
| Receptors, Cell Surface | 2 | 1998 | 902 | 0.010 |
Why?
|
| Aorta | 1 | 2006 | 666 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 454 | 0.010 |
Why?
|
| Animals, Congenic | 1 | 2001 | 9 | 0.010 |
Why?
|
| Medical Records | 1 | 2003 | 442 | 0.010 |
Why?
|
| Skin Tests | 1 | 1982 | 101 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 270 | 0.010 |
Why?
|
| Acid Phosphatase | 2 | 1994 | 56 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 861 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 697 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1983 | 253 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1982 | 309 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2003 | 454 | 0.010 |
Why?
|
| DNA-Formamidopyrimidine Glycosylase | 1 | 2000 | 7 | 0.010 |
Why?
|
| Arginine | 1 | 2004 | 506 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 565 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 887 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 1990 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2003 | 825 | 0.010 |
Why?
|
| Splenic Neoplasms | 1 | 2001 | 124 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2005 | 1042 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 1523 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2001 | 258 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 2001 | 187 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2000 | 164 | 0.010 |
Why?
|
| Genitalia, Female | 1 | 2000 | 83 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 1691 | 0.010 |
Why?
|
| Kinetics | 1 | 2003 | 2209 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1992 | 2488 | 0.010 |
Why?
|
| Mitogens | 1 | 1979 | 80 | 0.010 |
Why?
|
| Reoperation | 1 | 2004 | 1394 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 2000 | 69 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2001 | 349 | 0.010 |
Why?
|
| Cornea | 1 | 2004 | 681 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1999 | 148 | 0.010 |
Why?
|
| Transcription Factors, TFII | 1 | 1999 | 23 | 0.010 |
Why?
|
| Transcription Factor TFIID | 1 | 1999 | 27 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 1999 | 55 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 1999 | 57 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2005 | 1032 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1999 | 146 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1999 | 136 | 0.010 |
Why?
|
| Splenic Diseases | 1 | 1979 | 59 | 0.010 |
Why?
|
| Abdomen | 1 | 2001 | 347 | 0.010 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 1998 | 25 | 0.010 |
Why?
|
| Metaplasia | 1 | 2000 | 388 | 0.010 |
Why?
|
| Mucin-1 | 1 | 1999 | 158 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2000 | 385 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 1999 | 136 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2003 | 670 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 205 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1999 | 261 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1999 | 200 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 1998 | 90 | 0.010 |
Why?
|
| DCC Receptor | 1 | 1998 | 13 | 0.010 |
Why?
|
| Epidermis | 1 | 1999 | 197 | 0.010 |
Why?
|
| Retreatment | 1 | 1999 | 449 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 1999 | 219 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 1999 | 198 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 1998 | 89 | 0.010 |
Why?
|
| Angiography | 1 | 1999 | 349 | 0.010 |
Why?
|
| Megestrol | 1 | 1997 | 15 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 691 | 0.010 |
Why?
|
| Cystadenoma | 1 | 1997 | 28 | 0.010 |
Why?
|
| Estrone | 1 | 1997 | 32 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1997 | 204 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1998 | 205 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2005 | 1475 | 0.010 |
Why?
|
| Life Tables | 1 | 1997 | 119 | 0.010 |
Why?
|
| Ovarian Cysts | 1 | 1997 | 41 | 0.010 |
Why?
|
| Papilloma | 1 | 1997 | 86 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1997 | 251 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2003 | 1347 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1997 | 127 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1982 | 1822 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2003 | 840 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1998 | 472 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 1998 | 210 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1999 | 381 | 0.010 |
Why?
|
| Histiocytes | 1 | 1997 | 94 | 0.010 |
Why?
|
| Smad4 Protein | 1 | 1998 | 201 | 0.010 |
Why?
|
| Histiocytosis | 1 | 1997 | 55 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1996 | 54 | 0.010 |
Why?
|
| Drosophila Proteins | 1 | 2003 | 887 | 0.010 |
Why?
|
| Genome | 1 | 2000 | 689 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 1998 | 249 | 0.010 |
Why?
|
| Multigene Family | 1 | 1998 | 469 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1996 | 87 | 0.010 |
Why?
|
| Ischemia | 1 | 1999 | 400 | 0.010 |
Why?
|
| Mitotane | 1 | 1995 | 41 | 0.010 |
Why?
|
| Immunochemistry | 1 | 1995 | 60 | 0.010 |
Why?
|
| Sepharose | 1 | 1995 | 35 | 0.010 |
Why?
|
| Goiter | 1 | 1995 | 17 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1999 | 482 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2000 | 2142 | 0.010 |
Why?
|
| Lectins | 1 | 1995 | 146 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1995 | 129 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 2003 | 5679 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2000 | 1306 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1996 | 748 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2000 | 1297 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1993 | 53 | 0.010 |
Why?
|
| Myoglobin | 1 | 1993 | 117 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 1999 | 605 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1998 | 1032 | 0.010 |
Why?
|
| Vinblastine | 1 | 1994 | 462 | 0.010 |
Why?
|
| Necrosis | 1 | 1995 | 593 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 1995 | 493 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 1408 | 0.010 |
Why?
|
| Vacuoles | 1 | 1993 | 48 | 0.010 |
Why?
|
| Maxilla | 1 | 1993 | 89 | 0.010 |
Why?
|
| Glycogen | 1 | 1993 | 81 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 1993 | 109 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1992 | 44 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1994 | 502 | 0.010 |
Why?
|
| Uterus | 1 | 1997 | 798 | 0.010 |
Why?
|
| Thymidine | 1 | 1992 | 167 | 0.010 |
Why?
|
| Orbit | 1 | 1993 | 209 | 0.010 |
Why?
|
| Pancreas | 1 | 1996 | 739 | 0.010 |
Why?
|
| Tracheal Neoplasms | 1 | 1992 | 44 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1998 | 1301 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1992 | 286 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1991 | 65 | 0.010 |
Why?
|
| G2 Phase | 1 | 1991 | 218 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1998 | 1929 | 0.010 |
Why?
|
| Nervous System Neoplasms | 1 | 1990 | 35 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 1993 | 526 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1995 | 637 | 0.010 |
Why?
|
| Mucins | 1 | 1991 | 289 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1990 | 116 | 0.010 |
Why?
|
| Serotonin | 1 | 1990 | 287 | 0.000 |
Why?
|
| Hysterectomy | 1 | 1992 | 654 | 0.000 |
Why?
|
| Specimen Handling | 1 | 1990 | 308 | 0.000 |
Why?
|
| Genetic Testing | 1 | 1996 | 1692 | 0.000 |
Why?
|
| Intestinal Mucosa | 1 | 1994 | 1115 | 0.000 |
Why?
|
| Infant, Premature | 1 | 1993 | 843 | 0.000 |
Why?
|
| Antigens, CD | 1 | 1992 | 1420 | 0.000 |
Why?
|
| Glioblastoma | 1 | 1997 | 1776 | 0.000 |
Why?
|
| Glioma | 1 | 1997 | 1986 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1992 | 2440 | 0.000 |
Why?
|
| Phytohemagglutinins | 1 | 1983 | 72 | 0.000 |
Why?
|
| Complement C5a | 1 | 1983 | 32 | 0.000 |
Why?
|
| Job Syndrome | 1 | 1983 | 22 | 0.000 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1983 | 174 | 0.000 |
Why?
|
| Liver | 1 | 1971 | 3063 | 0.000 |
Why?
|
| Neutrophils | 1 | 1983 | 855 | 0.000 |
Why?
|
| Radiation Effects | 1 | 1971 | 23 | 0.000 |
Why?
|
| Gerbillinae | 1 | 1971 | 54 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1971 | 146 | 0.000 |
Why?
|
| Liver Function Tests | 1 | 1971 | 185 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1971 | 214 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1971 | 238 | 0.000 |
Why?
|
| Bilirubin | 1 | 1971 | 226 | 0.000 |
Why?
|